Diplopia

A 40-year-old African-American male patient presented to our clinic for his first eye exam with a complaint of new onset horizontal diplopia for several days. He reported it was worse at distance and when looking to his left. He denied trauma, headache, redness or vision changes in either eye.

A 47-year-old man presented to the emergency department at the University of New Mexico with 4 days of diplopia and bilateral retro-orbital pain. He had been feeling well until 2 weeks earlier when he developed a flu-like illness with fever, chills, myalgias, nausea and vomiting. These symptoms resolved without treatment. Subsequently, the patient developed double vision and ocular pain. On review of symptoms, he also reported new unsteadiness with walking as well as right-sided facial and eyelid drooping.

IMVT-1401, a thyroid eye disease treatment candidate, showed a 65% improvement in IgG levels in a phase 2a proof-of-concept study, Immunovant announced in a press release.

A 20-year-old woman presented for a neuro-optometric exam with complaints of headaches, asthenopia, occasional diplopia, extreme light sensitivity, dizziness and loss of balance. She reported her symptoms started about 2 years ago with day-to-day fluctuations in her symptoms.

CHICAGO — Among adults with recent-onset thyroid eye disease, those who received the monoclonal human antibody teprotumumab experienced substantial symptom relief and reported quality of life gains compared with those assigned placebo, according to pooled data from a phase 2 and a phase 3 clinical trial of the drug presented at the American Thyroid Association annual meeting.

SAN FRANCISCO — At the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting, Raymond Douglas, MD, PhD, of Cedars-Sinai Medical Center, discusses new data from the phase 3 OPTIC confirmatory clinical trial.

The FDA on Monday granted priority review of the investigational medication teprotumumab for treatment of thyroid eye disease, also known as Graves’ orbitopathy according to a press release from Horizon Therapeutics.

COEUR D’ALENE, Idaho — There is a high frequency of ocular manifestations in patients with multiple sclerosis, both at onset and during the disease course, according to a poster presented at the Women in Ophthalmology Summer Symposium.

An 18-year-old woman presented to Lahey Medical Center with 2 weeks of intermittent diplopia, nausea and headache.